Protalix Biotherapeutics Inc. buy klostergang
Start price
08.04.15
/
50%
€18.27
Target price
08.10.15
€24.00
Performance (%)
-46.14%
End price
08.10.15
€9.84
Summary
This prediction ended on 08.10.15 with a price of €9.84. The BUY prediction by klostergang for Protalix Biotherapeutics Inc. performed very badly with a performance of -46.14%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Protalix Biotherapeutics Inc. | -1.064% | -1.064% | -13.969% | -7.601% |
| iShares Core DAX® | 4.852% | -4.418% | 13.097% | 46.139% |
| iShares Nasdaq 100 | 3.999% | -3.283% | 31.335% | 76.067% |
| iShares Nikkei 225® | 4.221% | -6.223% | 44.472% | 47.139% |
| iShares S&P 500 | 3.324% | -3.174% | 24.360% | 57.683% |
Comments by klostergang for this prediction
In the thread Protalix Biotherapeutics Inc. diskutieren
Protalix BioTherapeutics
Protalex recently received FDA clearance to begin a Phase 1/2 study with PRTX-100 in Immune Thrombocytopenia (ITP).
Previous data with PRTX-100 in patients with Rheumatoid Arthritis (RA) demonstrated the drug to be both safe and highly efficacious.
(Laufzeit überschritten)